Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Eli Lilly and Company is a drug manufacturers - general business based in the US. Eli Lilly and Company shares (LLY) are listed on the NYSE and all prices are listed in US Dollars. Eli Lilly and Company employs 43,000 staff and has a trailing 12-month revenue of around $34.1 billion.
| Latest market close | $733.51 |
|---|---|
| 52-week range | $389.00 - $800.78 |
| 50-day moving average | $762.18 |
| 200-day moving average | $619.72 |
| Wall St. target price | $826.94 |
| PE ratio | 126.6782 |
| Dividend yield | $4.52 (0.71%) |
| Earnings per share (TTM) | $5.78 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $733.51 from 2024-04-26
| 1 week (2024-04-19) | 0.99% |
|---|---|
| 1 month (2024-03-27) | -5.74% |
| 3 months (2024-01-26) | 14.75% |
| 6 months (2023-10-27) | 30.93% |
| 1 year (2023-04-27) | 87.91% |
|---|---|
| 2 years (2022-04-27) | 162.71% |
| 3 years (2021-04-27) | 304.34% |
| 5 years (2019-04-26) | 547.10% |
Valuing Eli Lilly and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $34.1 billion |
|---|---|
| Operating margin TTM | 34.14% |
| Gross profit TTM | $21.9 billion |
| Return on assets TTM | 11.88% |
| Return on equity TTM | 48.44% |
| Profit margin | 15.36% |
| Book value | $11.98 |
| Market Capitalization | $709 billion |
TTM: trailing 12 months
Dividend payout ratio: 74.21% of net profits
Recently Eli Lilly and Company has paid out, on average, around 74.21% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.71% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 0.71% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $4.52 per share.
Eli Lilly and Company's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Eli Lilly and Company's most recent dividend payout was on 7 March 2024. The latest dividend was paid out to all shareholders who bought their shares by 13 February 2024 (the "ex-dividend date").
Eli Lilly and Company's shares were split on a 2:1 basis on 15 October 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.
Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as $389.0036 up to $800.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.367. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc. ; F.
A deep dive into the highlights and limitations of NinjaTrader.
A deep dive into the highlights and limitations of Frec.
Explore the best bonuses for opening a new brokerage account.
We analyzed a number of bitcoin ETFs to determine which are best to invest in.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
A deep dive into the highlights and limitations of Robinhood.